Overview

* Alkermes Q2 2025 revenue of $390.7 mln beats analyst expectations

* GAAP net income for Q2 2025 was $87.1 mln with diluted EPS of $0.52

* Revenue growth driven by strong performance of proprietary products

Outlook

* Alkermes ( ALKS ) reiterates 2025 financial expectations as per Feb. 12 press release

Result Drivers

* PROPRIETARY PRODUCT SALES - Strong performance across Vivitrol, Aristada, and Lybalvi drove revenue growth

* MEDICAID UTILIZATION - Gross-to-net favorability from Medicaid adjustments contributed to revenue increase

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $390.70 $341.60

Revenue mln mln (15

Analysts

)

Q2 EPS $0.52

Q2 Net $87.10

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Alkermes Plc ( ALKS ) is $42.00, about 37.7% above its July 28 closing price of $26.15

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)